Compare MTZ & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTZ | BIO |
|---|---|---|
| Founded | 1929 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9B | 10.3B |
| IPO Year | 2005 | 1994 |
| Metric | MTZ | BIO |
|---|---|---|
| Price | $165.56 | $368.98 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 22 | 3 |
| Target Price | $301.09 | ★ $356.67 |
| AVG Volume (30 Days) | ★ 1.7M | 214.6K |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.12 | 142.61 |
| EPS | 4.32 | ★ 11.25 |
| Revenue | ★ $14,299,171,000.00 | $2,583,200,000.00 |
| Revenue This Year | $27.91 | N/A |
| Revenue Next Year | $17.46 | $1.86 |
| P/E Ratio | $39.60 | ★ $31.96 |
| Revenue Growth | ★ 16.22 | 0.65 |
| 52 Week Low | $147.49 | $236.73 |
| 52 Week High | $441.43 | $396.23 |
| Indicator | MTZ | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 38.71 | 48.04 |
| Support Level | $164.31 | $364.41 |
| Resistance Level | $198.23 | $392.10 |
| Average True Range (ATR) | 12.07 | 12.73 |
| MACD | 0.37 | -1.54 |
| Stochastic Oscillator | 30.85 | 38.11 |
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. Its primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; pipeline infrastructure; power delivery; and other.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.